# Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors

> **NCT02587962** · PHASE1,PHASE2 · TERMINATED · sponsor: **Medivir** · enrollment: 34 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Birinapant
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02587962
- **Lead sponsor:** Medivir
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-04
- **Primary completion:** 2020-02-17
- **Final completion:** 2020-02-17
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Based on a futility analysis, the data monitoring committee recommended to stop enrollment.
- **Last updated:** 2021-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02587962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02587962, "Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02587962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*